Allucent d.o.o. Beograd
Allucent d.o.o. Beograd is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
Sponsor Immutep
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Allucent d.o.o. Beograd?
The 2026-10-09 snapshot links Allucent d.o.o. Beograd to 2 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Safety database, Safety reporting & pharmacovigilance. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Allucent d.o.o. Beograd?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Allucent d.o.o. Beograd conducted?
The linked trials record locations in 16 countries, including Belgium, Germany, Spain, Greece, Italy. These are trial locations, not confirmed office locations or countries where Allucent d.o.o. Beograd delivered services.
What can this page tell me about Allucent d.o.o. Beograd's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Allucent d.o.o. Beograd. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Allucent d.o.o. Beograd